

**SSBH 2021
Curriculum Vitae**

Name	Dennis Black
Organization	University of California, San Francisco
Position & Title	Professor in Residence, Step 8 Epidemiology & Biostatistics School of Medicine

Educational background & Professional experience

1969 - 1973	University of California, Berkeley, B.A., Zoology
1976 - 1978	University of California, Berkeley, M.A., Biostatistics
1982 - 1987	University of California, Berkeley, Ph.D., Biostatistics
1978 - 1981	US Public Health Service Hospital, San Francisco, CA, Research Coordination Branch, Biostatistician
1981 - 1987	University of California, San Francisco, Department of Epid. and International Health, Clinical Epidemiology Program, Senior Biostatistician
1987 - 1993	University of California, San Francisco, Division of Clinical Epidemiology, Assistant Adjunct Professor
1993 - 1999	University of California, San Francisco, Department of Epidemiology and Biostatistics, Associate Adjunct Professor
1999 - 2002	University of California, San Francisco, Department of Epidemiology and Biostatistics, Adjunct Professor
2002 - present	University of California, San Francisco, Department of Epidemiology and Biostatistics, Professor in Residence
2005 - 2010	University of California, San Francisco, Div. of Clinical Trials and Multicenter Studies, Head
2010 - present	University of California, San Francisco, Division of Chronic Diseases, Head

Research Interests

Osteoporosis, randomized trials, antiresorptive treatment, parathyroid hormone

Publications

Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. **Lancet**. 348:1535-41, 1996.

Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ; PaTH Study Investigators. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. **N Engl J Med** 349(13):1207-15, 2003

Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, Lang TF, McGowan JA, Rosen CJ, the PaTH Study Investigators. One Year of Alendronate after One Year of Parathyroid Hormone (1-84) for Osteoporosis. **N Engl J Med** 2005 Aug 11(353): 555-565.

Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR; FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: The Fracture Intervention Trial Long-term Extension (FLEX): A Randomized Trial. **J Amer Med Assoc** 2006 Dec; 296(24):2927-38.

Black, DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman R, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosaria-Jansen T, Krasnow J, Hue T, Sellmeyer D, Eriksen EF, Cummings SR; for the Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly (HORIZON) - Pivotal Fracture Trial Group. Once-yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. **N Engl J Med**. 2007 May; 356: 1809-22.

Black DM, Kelly MP, Genant HK, Palermo L, Eastell R, Bucci-Rechtweg C, Cauley J, Leung PC, Boonen S, Santora A, de Papp A, Bauer DC; Bisphosphonates and Fractures of the Subtrochanteric or Diaphyseal Femur. **NEJM**, 2010 Mar 24 (PMID 20335571)

Black DM, Bauer DC, Schwartz AV, Cummings SR, Rosen CJ. Continuing Bisphosphonate Treatment for Osteoporosis - For Whom and for How Long? **N Engl J Med**. 2012 May;366:2051-2053.

Black DM, Rosen CJ. "Postmenopausal osteoporosis." *New England Journal of Medicine* 374.3 (2016): 254-262.

Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials. *Lancet Diabetes Endocrinol*. 2020 08; 8(8):672-682. **Black DM**, Bauer DC, Vittinghoff E, Lui LY, Grauer A, Marin F, Khosla S, de Papp A, Mitlak B, Cauley JA, McCulloch CE, Eastell R, Bouxsein ML. PMID: 32707115.

Black, DM, Geiger, EJ, Eastell, R, Vittinghoff, E, Li, BH, Ryan, DS, Dell, RM, Adams, AL. Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates *N Engl J Med* 2020; 383:743-753; [8/20/2020](#). DOI: 10.1056/NEJMoa1916525
